Search
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. … It blocks some of the enzymes that keep cancer cells from dying.
Synonyms: (R)-4-(3-Morpholin-4-Yl-1-Phenylsulfanylmethyl-Propylamino)-N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-Enylmethyl]-Piperazin-1-Yl}-Benzoyl)-3-TrifluoromethanesulfonylbenzenesulfonamideTrapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
Categories: Vasodilators Used in Cardiac DiseasesSAR443122
go.drugbank.com/drugs/DB16492InvestigationalSAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. … Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus.
Synonyms: 1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDEDofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
TA-NIC
go.drugbank.com/drugs/DB05445InvestigationalIt is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive … TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.
Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16711ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10287ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10288ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10290ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination